ANBL17P1
ANBL17P1 tested whether the antibody dinutuximab, which works against relapsed neuroblastoma, can be given from the very start of treatment alongside induction chemotherapy for newly diagnosed high-risk disease; none of the 42 children had unacceptable toxicity, which opened the way to the randomised trial now under way.
Overview
ANBL17P1 was a Children's Oncology Group single-arm pilot study in 42 children with newly diagnosed high-risk neuroblastoma. Dinutuximab and sargramostim (GM-CSF) were added to cycles 3 to 5 of the standard induction chemotherapy (cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, doxorubicin), followed by surgery, tandem autologous transplant, radiotherapy and post-consolidation immunotherapy. The primary endpoints were the percentage of patients with unacceptable toxicity and the percentage who were feasibility failures over the first five cycles.
In the registry results neither endpoint recorded a single patient (0 percent for both). The regimen carried into the randomised phase 3 ANBL1531 amendment testing dinutuximab in induction, and the corpus's neuroblastoma page cites ANBL17P1 for adding dinutuximab to induction.
- 0 out of 100 people reached this endpoint with Induction chemotherapy + dinutuximab + GM-CSF.
- 0 out of 100 people reached this endpoint with Induction chemotherapy + dinutuximab + GM-CSF.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Newly diagnosed high-risk neuroblastoma: a pilot induction regimen adding the anti-GD2 antibody dinutuximab and GM-CSF to the standard five-cycle chemotherapy induction, followed by tandem transplant and radiotherapy, with unacceptable toxicity and feasibility as the primary endpoints. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (GD2); the result should not be assumed for people whose cancer does not have it.
- Only 42 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Similar pages
not linked directly; found by shared links- TrialANBL0531
Shares Topotecan, Childhood cancers (all types), Children's Oncology Group (COG), Etoposide and the tag soc-trials.
- TrialANBL1221
Shares Sargramostim, Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Childhood cancers (all types) and the tag soc-trials.
- TrialACNS0333
Shares Autologous stem cell transplant (high-dose therapy), Childhood cancers (all types), Children's Oncology Group (COG), Vincristine and the tag soc-trials.
- TrialAEWS0031
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.
- TrialEuroNet-PHL-C2
Shares Childhood cancers (all types), Vincristine, Etoposide, Cyclophosphamide and the tag soc-trials.
- TrialAHOD1331
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.
- TrialACNS1422
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag soc-trials.
- TrialACNS0121
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.